Further investigation by Kim et al. (2017) highlighted the potential of combining an MEK inhibitor with CDK4/6 inhibitors for treating MM with oncogenic BRAF fusions [34]. This evidence concerns the gene MAP2K7 and Miyoshi myopathy.